Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 833
Diversity, Equity and Access to HIV Research
On May 2, 2024, AVAC staffer Jessica Salzwedel gave a presentation on diversity, equity and access in HIV research at the Ending the HIV Epidemic Conference at Weill Cornell Medicine. Check out the full presentation in PDF format. “When we...
Prevention Option:
Will the Pandemic Accord Fail to Learn the Lessons of the HIV Response?
The Office of the United Nations High Commissioner for Human Rights (OHCHR) highlighted that from the HIV experience we know that if public health measures do not take human rights into account, we will leave marginalised populations behind, fail to address structural barriers to access to quality healthcare, and miss essential interventions altogether.
More and More Evidence that Choice is the Key
AVAC convened three important conversations in the last month on new data that delivered the analysis and evidence that choice and equity in access to PrEP products can make the difference between real-world population-level impact or an epidemic marching on for many years to come.
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through the end of 2024.
Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025
Malaysia, Nigeria, Peru, Zambia, and the European Medicines Agency have approved CAB for PrEP; ViiV also made submissions in Canada, Colombia, and the United Kingdom. There are now 13 regulatory approvals and 15 additional submissions that are pending.
Prevention Option:
HIV Vaccine and Antibody Efficacy Trials to Date
This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.
Prevention Option:
Joint Statement on the April 18th Revised Pandemic Accord Draft
The Coalition of Advocates for Global Health and Pandemic Preparedness, a group of organizations advocating for a holistic and equitable approach in pandemic preparedness, offers several revisions to the April 18 revised Pandemic Accord draft.
Prevention Option:
Biomedical HIV Prevention Summit and PrEP in Black America Summit
1,000+ community advocates, researchers, policy experts, federal public health leadership, medical and service providers attended the NMAC annual Biomedical HIV Prevention Summit in Seattle. The discussion and debate on PrEP access, especially for racial and ethnic minorities and key populations, PrEP research, care, policy and community-based programs are ones to follow.
Prevention Option:
PxPulse: The Advocacy Chronicles with APHA’s Yvette Raphael
Our debut episode of the Advocacy Chronicles features Yvette Raphael, the Executive Director of Advocacy for Prevention of HIV and AIDS (APHA) in South Africa, and a leader in the development of The Choice Manifesto.
For Us by Us: PrEP in Black America – A Master Plan for HIV Prevention in Black America
In the spirit of seeking change to ameliorate the devastating impact of HIV in Black communities through biomedical HIV prevention, Black leaders convened the “PrEP in Black America (PIBA) Summit” virtually and in person on September 13, 2022,...
Prevention Option:
showing 1-10 of 833